Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1

Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1

Increasing evidences indicate that in Myotonic Dystrophy type 1 (DM1 or Steinert disease), an autosomal dominant multisystem disorder caused by a (CTG)n expansion in DMPK gene on chromosome 19q13. 3, is the most common form of inherited muscular dystrophy in adult patients with a global prevalence o...

Full description

Bibliographic Details
Main Authors: Costanza Simoncini, Giulia Spadoni, Elisa Lai, Lorenza Santoni, Corrado Angelini, Giulia Ricci, Gabriele Siciliano
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Neurology
Subjects:
myotonic dystrophy type 1
central nervous system
clinical trials
neuropsychological outcome measures
neuroimaging
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00624/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00624/full

Similar Items